Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alpharma to resubmit new drug application for Embeda
While the initial new drug application (NDA) submission qualified for a priority review, certain technical issues around data presentation prevented a complete evaluation by the FDA within the
While the initial new drug application (NDA) submission qualified for a priority review, certain technical issues around data presentation prevented a complete evaluation by the FDA within the
But the study did not demonstrate a statistically significant prolongation of overall survival, a secondary endpoint, for either dose in combination with gemcitabine and cisplatin chemotherapy compared to
The term sheet includes certain worldwide cross-licenses under which each party receives a royalty-free license under all existing patents of the other party for its respective existing capsule
Sanofi Pasteur, the vaccines division of Sanofi-Aventis, plans to invest C$100 million in a state-of-the-art facility at the company’s Connaught Campus in north Toronto, Canada. The Government of
In the first-quarter 2008, Norvasc and Zyrtec revenues decreased by $556 million and $344 million, respectively, compared with the same quarter of 2007. For the first-quarter 2008, Pfizer
The agreement grants Echo exclusive rights of first negotiation to all dermatology product and transdermal drug delivery technology opportunities identified or acquired by Cato BioVentures. Patrick Mooney, Echo’s
Nimodipine soft gel capsules are the generic equivalent of Nimotop capsules marketed by Bayer. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and
Under the agreement, Vernalis will receive approximately E18.4 million in cash from Paul Capital Healthcare and, in return, Paul Capital Healthcare will receive approximately 90% of Menarini’s payments
The Phase Ib clinical trial, which tested either 1.25 or 2.5 grams of SRT501 given twice daily to Type 2 diabetic patients, found that the patient group receiving
Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications.